Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sotalol: a breakthrough antiarrhythmic?

J M Nappi1, P L McCollam

  • 1Department of Hospital Pharmacy Practice and Administration, College of Pharmacy, Medical University of South Carolina, Charleston 29425.

The Annals of Pharmacotherapy
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose Titration, Persistence, and Adherence to Statin Therapy Among Patients with High-Risk Vascular Disease in Japan.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Tenecteplase for treatment of acute myocardial infarction.

The Annals of pharmacotherapy·2001
Same author

A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2001
Same author

Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2001
Same author

New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.

The Annals of pharmacotherapy·2001
Same author

Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes.

Pharmacotherapy·2001
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Sotalol, a Class III antiarrhythmic, effectively treats life-threatening ventricular arrhythmias. While generally well-tolerated, potential adverse effects include proarrhythmia, necessitating careful patient monitoring.

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiology
  • Clinical Pharmacy

Background:

  • Sotalol exhibits both beta-blocking (Class II) and action potential prolonging (Class III) antiarrhythmic properties.
  • The Class III activity, primarily attributed to both isomers, is more pronounced at higher plasma concentrations than beta-blockade.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, dosing, adverse effects, and therapeutic applications of sotalol.
  • To synthesize current knowledge on sotalol's efficacy and safety profile.

Main Methods:

  • Comprehensive literature search using "sotalol" as the keyword.
  • Inclusion of relevant animal studies, human trials, and case reports.
  • Assessment of literature for quality, methodology, and outcome data.

Related Experiment Videos

Main Results:

  • Sotalol is a racemic compound with dual antiarrhythmic actions, categorized as a Class III agent.
  • Pharmacokinetic profile: >90% oral absorption, 2-4h peak concentration, ~12h half-life, primarily renally excreted.
  • Effective in refractory life-threatening ventricular arrhythmias; adverse effects often linked to beta-blockade; risk of proarrhythmia exists.

Conclusions:

  • Racemic sotalol is FDA-approved for documented life-threatening ventricular arrhythmias.
  • Ongoing investigations explore sotalol for supraventricular arrhythmias and its d-isomer.
  • Sotalol represents a significant therapeutic option for specific cardiac arrhythmias.